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Structured Summary
Background—The recently updated White House National HIV/AIDS Strategy (NHAS) 
includes specific progress indicators for improving the HIV care continuum, but the economic and 
epidemiological impact of achieving those indicators remains unclear.
This manuscript version is made available under the CC BY-NC-ND 4.0 license.
Corresponding author: Maunank Shah, MD PhD, Johns Hopkins University, School of Medicine, Department of Medicine, Division 
of Infectious Diseases, 725 N. Wolfe St. PCTB building-224. Baltimore, MD, USA 21205, Phone: 443-287-0401 Fax: 410-955-0740, 
mshah28@jhmi.edu.
*Full professors
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Research in Context:
Evidence before this study: We searched PubMed to identify studies related to the National HIV/AIDS strategy (NHAS), and 
mathematical models of the care continuum in the US. We searched terms (“HIV” or “AIDS”) and (“National HIV/AIDS strategy” or 
“model” or “continuum”) and included all studies published from 2010 (initial NHAS release) until November 16, 2015 without 
language restrictions. Our search identified no models or epidemiological studies related to the recently updated US National HIV/
AIDS strategy. Our search identified one cost-effectiveness analysis of the prior 2010 NHAS linkage to care target, that showed 
improved early linkage would cost an extra $62,200 per QALY-gained. Our prior mathematical model of HIV transmission in the US 
suggested that improving yearly rates of retention in care by 50% could avert 35% of new infections.
Added Value of this Study
Our results demonstrate that achieving the updated NHAS progress indicators of 90% awareness of HIV serostatus, 85% rapid 
linkage, and 90% of diagnosed individuals in care by 2020 could allow the United States to reach NHAS epidemiological goals and 
halve new infections over 10 years with eventual reductions in HIV prevalence. The primary driver of this achievement (and also the 
progress indicator furthest from being met) is retention in care. Meeting NHAS care targets would require an increase of $105 billion 
of HIV care costs compared to continuation of current practice; the majority of these additional costs represent ART costs for PLWH 
who are not currently virally suppressed.
Implications of all the available evidence: The evidence suggests that continuous retention in care is critical for long term success in 
HIV treatment. Meeting the NHAS progress indicators for improved HIV screening, linkage, and care-engagement could alter the 
trajectory of the US HIV epidemic, but will require continued and increased investment. ART drug prices are the most influential 
drivers of cost in meeting the goals of improving HIV care engagement.
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Methods—We constructed a dynamic transmission model of HIV progression and care 
engagement to project HIV incidence, prevalence, mortality, and costs among adults in the United 
States over ten years. We specifically considered achievement of the 2020 targets set forth in 
NHAS progress indicator 1 (90% awareness of serostatus), indicator 4 (85% linkage within one 
month), and indicator 5 (90% of diagnosed individuals in care).
Finding—At current rates of engagement in the HIV care continuum, we project 524,000 (95% 
Uncertainty Range 442,000 – 712,000) new HIV infections and 375,000 deaths (364,000 – 
578,000) between 2016 and 2025. Achieving NHAS progress indicators 1 and 4 has modest 
epidemiologic impact (new infections reduced by 2·0% and 3·9%, respectively). By contrast, 
increasing the proportion of diagnosed individuals in care (indicator 5) averts 52% (47-56%) of 
new infections. Achieving all NHAS targets resulted in a 58% reduction (52%-61%) in new 
infections and 128,000 lives saved (106,000-223,000) at an incremental health system cost of 
$105 billion dollars.
Interpretation—Achievement of NHAS progress indicators for screening, linkage, and 
particularly improving retention in care, can substantially reduce the burden of HIV in the United 
States.
Introduction
Since the HIV care continuum in the United States (US) was first described1, stakeholders at 
the federal, state and local levels have sought to identify and address gaps at each step of the 
cascade. These steps include HIV diagnosis, linkage to medical care, retention, prescription 
of antiretroviral therapy [ART], and viral suppression. Broader screening and early ART 
initiation have been shown to confer both therapeutic and preventive benefits2, 3. However, 
2012 figures from the Centers for Disease Control and Prevention (CDC) indicate that of the 
estimated 1·2 million people living with HIV (PLWH) in the US, approximately one out of 
eight remained unaware of their infection, and only three out of ten achieved viral 
suppression4. Given that more than 90% of transmissions have been estimated to be 
attributable to PLWH who were either undiagnosed or not retained in medical care5, the 
need for sustained and coordinated efforts along the continuum is tremendous.
In 2013, the HIV Care Continuum Initiative was established to accelerate progress towards 
specific quantitative goals outlined in the first comprehensive National HIV/AIDS Strategy 
(NHAS)6. The White House recently updated the NHAS care continuum targets to 90% of 
PLWH knowing their serostatus (progress indicator 1), 85% of newly diagnosed individuals 
linking to clinical care within one month of their diagnosis (progress indicator 4), and 90% 
of diagnosed individuals engaged in HIV medical care (progress indicator 5)7. These align 
closely with the Joint United Nations Programme on HIV/AIDS (UNAIDS) ambitious 
90-90-90 targets seeking to end the epidemic as a major global health threat by 20308.
The current 2015 NHAS additionally contains two epidemiological targets: reduction in the 
number of new HIV diagnoses of at least 25% by 2020 (progress indicator 2) and a 
reduction in mortality among persons diagnosed with HIV of 33% (progress indicator 8). 
However, the extent to which achieving revised NHAS progress indicators for improved 
screening, linkage, and care engagement would advance progress toward these 
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epidemiological targets, and the magnitude of resources required to achieve desired levels of 
coverage have not yet been quantified. Therefore, we constructed a dynamic transmission 
model to project incident HIV infections, prevalence, mortality, and health care costs over 
the next ten years (2016-2025). For each outcome, we modeled the impact of attaining the 
three 2020 national progress indicators for serostatus awareness, linkage to care, and 
retention.
Methods
Model description
The Johns Hopkins HIV economic-epidemic model (JHHEM)9, 10 is a compartmental model 
of the US HIV epidemic that incorporates transmission, disease progression, and health 
system engagement. A full description has been published previously9. Briefly, our model 
partitions the adult population (18 to 78 years) of the US based on sex, age, HIV infection, 
and transmission category (heterosexuals, men who have sex with men [MSM], and people 
who inject drugs [PWID]). PLWH are further characterized by CD4 strata and location on 
the HIV care continuum (e.g. unaware of HIV status, aware but out of care, in care but not 
on ART, on ART but not virologically suppressed, and virologically suppressed). HIV 
infection, transition through the care continuum, and demographic changes are modeled 
dynamically as a system of ordinary differential equations9.
The model parameters (Table 1) 3, 11-18 were updated and calibrated to reflect most recent 
CDC data on the US HIV epidemic and continuum of care4, 9, 19 (Supplement). The model 
incorporates HIV transmission through sex (heterosexual or male homosexual) and through 
needle sharing. We explicitly modeled rates of annual HIV testing, initial linkage to care, 
discontinuation and reengagement in care, and ART initiation, calibrating those rates to 
reflect current national estimates of engagement in the continuum of care19, 20 
(Supplemental Figure 3). To determine transmission probabilities during model calibration 
(average yearly partnerships and probability of transmission per partnership), we brought the 
model to equilibrium in 2006 and then allowed population growth, identifying parameter 
values in an iterative process for which the model outputs best reflected epidemiologic data 
on incidence and prevalence between 2007-2012 (model projections and CDC estimates 
shown in Supplemental Figure 24, 19).
Statistical Anlaysis
Our primary outcomes were HIV incidence, prevalence, mortality and health care costs over 
a 10-year time horizon. In the base-case, we assumed implementation of updated guidelines 
that ART be initiated regardless of CD4 count21, but with continuation of current trends in 
the HIV care continuum 19, 20. We then estimated the epidemiologic and economic impact 
of reaching targets set forth in the new NHAS progress indicators (indicators 1, 4, and 5 
either individually or in combinations) by 2020 by comparing the following scenarios to the 
base-case:
• NHAS Indicator 1—“Increase the percentage of PLWH who know their serostatus 
to at least 90%”: We increased annual testing rates for high-risk individuals (MSM, 
PWID, and heterosexuals aged 18-30 years old), with ongoing screening at current 
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rates in the general population, to a level that would achieve 90% serostatus 
awareness by 2020. During model calibration of intervention scenarios, this 
corresponded to an approximate 50% increase compared to current annual testing 
rates among MSM, PWID, and young heterosexuals (Supplement).
• NHAS Indicator 4—“Increase the percentage of newly diagnosed persons linked to 
HIV medical care within 1 month of their HIV diagnosis to at least 85%”: We 
increased the proportion of newly diagnosed persons completing an HIV care visit 
within a month to 85% by 2020.
• NHAS Indicator 5—“Increase the percentage of persons with diagnosed HIV 
infection who are retained in HIV medical care to at least 90%”: We iteratively 
decreased the annual rate of disengagement in care (from 18-25% per year 
[depending on risk group] in the base-case to 4-6% per year), and increased the rate 
of reengagement in care among those out of care (from 12·5% per year to 50% per 
year), until the point that the proportion of serostatus-aware PLWH engaged in care 
was 90% in 2020 (Supplement).
Costs were calculated from a health-system perspective with a unit-costing (Table 1) 
approach that considers the person-time spent in each model compartment (e.g., person-time 
on ART) and the number of transitions between compartments (e.g. transition from unaware 
to aware as a result of HIV testing). In the base-case, we considered costs related to HIV 
testing, linkage referrals, and clinical care (e.g. viral loads, genotypes, ART usage, 
hospitalizations). We additionally included costs of existing retention in care services, based 
on staffing for social work, nurse-managers, and case-managers at local HIV clinics (base-
case, $300 per patient in care per year [range $50-$1500])9. All costs are reported in 2015 
US dollars; future costs were discounted at an annual rate of 3%22. Estimates of disease 
burden (e.g., infections or deaths) averted are reported without discounting.
In primary analysis we did not consider infrastructural or programmatic costs of 
interventions to improve the HIV care continuum. However, costs related to increased health 
care utilization when achieving NHAS targets as a result of increased care-engagement were 
incorporated (e.g. increased numbers of tests, increased ART usage). We explored a range of 
intervention costs in secondary analyses . We conducted a probabilistic uncertainty analysis 
by simultaneously varying all parameter values over beta distributions bounded by their 
ranges (Table 1). We report 95% uncertainty ranges (URs) as the 2·5th and 97·5th percentile 
of those simulations.
We performed all analyses using R version 3·0·1(R Foundation for Statistical Computing).
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication.
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Results
If the current rates of screening, linkage, and retention in care as part of the US HIV care 
continuum persists, approximately 524,000 (95%UR 442,000 – 712,000) new HIV 
infections would occur between 2016 and 2025 (Figure 1), with approximately 375,000 
deaths (from all causes) among PLWH (95%UR 364,000 – 578,000). This results in a 
projected prevalence of 1·47 million PLWH in 2025, of whom 39·7% (582,000) would be 
virally suppressed. HIV care would cost the US health system $254 billion (95%UR $186 
billion - $297 billion) with 3% discounting (Table 2) over the next decade ($295 billion 
without discounting). The epidemiologic and economic impact of achieving the three 2020 
NHAS targets for improving HIV awareness (progress indicator 1), linkage to care (progress 
indicator 4), and retention in care (progress indicator 5) is shown in Table 2 and Figure 1.
Increasing screening rates to allow achievement of NHAS indicator 1 (90% serostatus 
awareness by 2020) would avert 10,600 new HIV infections (95%UR 6,000-18,000), or a 
2·0% reduction (95%UR 1·1%-2·8%) over the next 10 years. However, improved screening 
alone has little impact on overall number of PLWH achieving viral suppression (589,000 of 
1·46 million PLWH, 40·3%) in 2025. Consequently, enhanced screening would avert only 
0·4% (1400) of deaths among PLWH during the analysis period, if current rates of care 
retention persist.
If 85% of those newly diagnosed with HIV were linked to care within 1 month (NHAS 
indicator 4), with current rates of screening and retention in care, the US would avert an 
estimated 20,600 (95%UR 14,000-35,000) HIV infections (3·9% reduction, 95%UR 
2·8-5·4), and would avert 11,600 (95%UR 8,000-25,000) deaths (3·1% reduction; 95%UR 
2·0%-4·9). In isolation, improved linkage would increase the percent of total PLWH that are 
virally suppressed to 41·1% (598,000 of 1·46 million PLWH).
Achieving the retention in care targets in NHAS progress indicator 5 (90% of diagnosed 
persons in care) was projected to avert a much larger disease burden: a 52·3% reduction 
(95%UR 47-56%) in HIV infections (274,000 infections averted, 95%UR 220,000 – 
372,000) and a 31·7% reduction (95%UR 24%-39%) in deaths (119,000 lives saved, 
95%UR 94,700-256,000) over 10 years (with 76·6% [999,000 of 1·30 million] of all PLWH 
virally suppressed), even at current rates of serostatus awareness and linkage to care.
Simultaneously improving all aspects of the HIV care continuum to reach all three NHAS 
care targets increased the estimated point prevalence of virological suppression among all 
PLWH (1.01 million of 1.29million PLWH) in 2025 from the base-case of 39·7% to 78·8% 
(82% of those diagnosed [1.24million]). Consequently, this scenario resulted in a 57·7% 
reduction (95%UR 52%-61%) in HIV infections (302,000 HIV infections averted, 95%UR 
240,000-421,000) and a 34·3% reduction (95% UR 26%-41%) in deaths (128,000 lives 
saved, 95%UR 106,000-223,000) (Table 2, Supplemental Figure 5). The increased testing, 
care-engagement, and ART usage if all NHAS care targets are met is projected to cost $105 
billion more over 10 years (with 3% discounting; $124 billion incremental increase without 
discounting) than if current levels of the HIV care continuum persisted (Table 2, 
Supplemental Figure 6).
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In one-way sensitivity analysis, total costs were most influenced by ART prices 
(Supplemental Figure 7 and 8). If ART prices could be reduced to the $10,000 per person-
year, costs in the current care continuum scenario dropped from $254 billion to $107 billion 
dollars; alternatively, if ART regimen costs rose to $45,000 per person-year, costs increased 
to $341 billion over 10 years. The incremental cost to achieve all NHAS care continuum 
targets likewise primarily reflected the costs related to increased ART usage (range of 
incremental NHAS achievement cost of $26 billion to $152 billion, for ART costs of 
$10,000 to $45,000 per person-year, respectively).
In a secondary analysis, we estimated health system costs inclusive of hypothetical 
intervention costs that would allow increased care engagement to achieve NHAS progress 
indicators. We explored up to a 20% increase in testing costs, along with an additional $500 
per person linking to care, additional $5,000 per person-year to improve retention in care 
(above current retention costs), and $1,000 per person re-engaged in care. In this scenario, 
the total costs (with 3% discounting) of achieving all three NHAS care targets (NHAS 1, 4 
and 5) was $408 billion (an increase of $49 billion [13·6% increase] compared to our 
primary NHAS analysis [without intervention costs], and an incremental increase of $154 
billion over the scenario of continued current continuum of care).
DISCUSSION
The US NHAS was updated in July 2015 with a vision to reduce new infections and provide 
high quality care for PLWH. Our model projects that there will be more than half million 
new HIV infections in the next decade if improvements to diagnosis and care are not 
realized. By contrast, our results suggest that this number can be cut by almost 60%, 
resulting in over 125,000 lives saved, if comprehensive steps are taken to achieve 2020 
targets for screening, linkage and care-engagement set forth in NHAS progress indicators. 
The primary gap in the current continuum of care is in care retention, which is needed to 
realize the prevention and health benefits of ART usage and viral suppression; achieving the 
NHAS goal of engaging 90% of those diagnosed in care could halve the number of HIV 
infections over the next 10 years. These results offer credence to the importance of 
achieving the NHAS progress indicators in order to ‘bend the curve’ of the HIV epidemic.
Currently, CDC estimates that over 85% of PLWH are aware of their serostatus, and there 
are recommendations to increase HIV screening among high-risk groups19, 23. As such, our 
modeling efforts found that incrementally increasing HIV diagnoses alone to meet NHAS 
targets (90% awareness by 2020), has relatively little impact on the overall HIV epidemic. 
The NHAS additionally outlines the need to increase the percentage of diagnosed PLWH 
who are virally suppressed to at least 80%. We found that increased screening and linkage 
alone is insufficient to meet this goal, due to inadequate long-term ART usage. By contrast, 
the effects of improved HIV screening and linkage could be greatly enhanced if coupled 
with improved care retention. Under the most intensive scenario, wherein screening, linkage, 
and proportion of PLWH in care are improved to meet the NHAS goals, nearly 82% of 
diagnosed PLWH are expected to be virally suppressed, exceeding the NHAS targets for 
viral suppression.
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The NHAS has also set ambitious epidemiological goals, including a 25% reduction in HIV 
diagnoses (as a surrogate for incident infections) and a 33% reduction in mortality among 
(diagnosed) PLWH by 2020. Our results suggest that both of these goals are within reach, 
but only by redoubling efforts to improve care retention. In particular, only when 
incorporating scenarios with a high proportion of PLWH in care do we observe significant 
declines in incidence (and mortality), with eventual reductions in the total number of PLWH 
over time. These results suggest that a change in thinking about the HIV response is 
necessary if we are to meaningfully bend the curve of HIV transmission. To date, most 
studies have evaluated the HIV care continuum cross-sectionally. However, continuous 
retention is required for long-term success in HIV treatment24. Specifically identifying 
evidence-based interventions to improve long term retention and close this gap in the HIV 
care continuum25 must be recognized as an urgent priority. Interventions such as housing 
assistance, case management, or opioid substitution therapy can be helpful, but ultimately 
we must develop a comprehensive, patient-centered approach to retention and re-
engagement in care that considers the diverse needs of PLWH and seeks to meet those needs 
in holistic fashion. Losing a patient to HIV care should be considered a “sentinel event,” 
with necessary structures put in place to prevent such events from ever occurring.
Our results also highlight the financial resources that are likely required to achieve these 
ambitious goals. Currently, the federal domestic HIV budget is $25·3 billion for fiscal year 
2016 (21% increase since 2010)26, a funding rate consistent with model projections of total 
HIV health system costs ($254 billion) over the next decade if the current HIV care 
continuum persists. In order to achieve levels of care retention necessary to change the 
trajectory of HIV epidemiology in the US, a similar restructuring in thinking regarding 
funding of the HIV/AIDS response may be required. Specifically, we estimate that 
achieving NHAS targets for serostatus awareness, linkage to care, and retention in care 
would cost an incremental $105 billion in health care costs alone over 10 years, representing 
an over 40% increase in expenditures – the vast majority of which represent additional costs 
of ART associated with a greater number of PLWH engaged in care. Thus, if we are to 
succeed in curbing transmission, we must also reframe our approach to funding the HIV 
response, seeking innovative and targeted funding mechanisms to facilitate this long term 
treatment and retention. Reducing ART costs through such mechanisms as 430B pricing, 
ADAP programs, and generic manufacturing of key drugs could offer marked health system 
cost savings.. Efforts to both expand funding for HIV care, including ancillary services and 
interventions to promote long term retention, and lower the costs of ART must both be 
prioritized.
Our results build on other models of HIV transmission in the US. A study assessing the 
impact of the original NHAS (2010) linkage goals found a similarly small impact of linkage 
interventions on transmission27. Compared to other authors28, our results suggest a 
relatively more modest impact on HIV incidence of expanded screening interventions. The 
current results also expand on prior efforts by our group to evaluate the impact of the care 
continuum on HIV transmission in the US5, 9. We now provide updated projections of 
incidence and prevalence incorporating recently revised estimates of HIV epidemiology and 
the care continuum4, 19, and quantify the economic and epidemiologic impact of achieving 
targets for care engagement within NHAS progress indicators.
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Our study has several limitations. For all scenarios, we assume that PLWH will have timely 
access to ART after entry into care, as per current guidelines. Delays or gaps in therapy 
would lessen the impact of increased care engagement. Our model is also calibrated to 
currently available national estimates of engagement in the care continuum19. Data from 
large city and county programs have generally suggested more optimistic estimates of 
current HIV care engagement and viral suppression29, 30. To the extent that engagement in 
care and viral suppression in our base-case scenario are underestimated, the incremental 
impact of achieving NHAS targets may be more modest, and our model may be 
optimistically biased. Bias in our model estimates may also result from applying nationally 
representative numbers to any specific city or locale. Nonetheless, our model provides 
absolute, in addition to relative, projections on incidence and prevalence with uncertainty 
ranges under various engagement in care scenarios, while reinforcing the importance of 
accurate national continuum of care estimates. Our model did not evaluate specific 
interventions (or associated costs) that will likely be needed to achieve NHAS targets. 
Efforts to improve testing, linkage, and improve adherence or care-engagement will almost 
certainly require a combination of health system, policy, and clinical innovations. 
Nonetheless, we conducted secondary analyses to explore costs inclusive of hypothetical 
HIV care continuum interventions and found modest relative to the health system costs 
attributable to increased ART usage and clinical care expected to incur with achieving 
NHAS targets. Our model also found a significant number of new infections despite 
achievement of comprehensive improvements to screening, linkage, and care engagement, 
suggesting that additional prevention strategies may be needed to reduce transmissions 
further. Our model does not address the potential costs and effects of scale up of pre-
exposure prophylaxis (PrEP), or other such prevention interventions that fall outside the care 
continuum. Improved HIV serostatus awareness with consequent consistent PrEP utilization 
could further decrease transmission among high risk groups, but could also substantially 
increase prevention costs.
In conclusion, our results offer quantitative evidence of the extent to which achievement of 
NHAS targets for improving HIV testing, linkage, and care-engagement impacts the parallel 
NHAS goals of reducing HIV incidence and prevalence. As the US moves to implement the 
new NHAS, our model suggests that sustained improvements to retention in care must be the 
highest priority to reach the ambitious epidemiological targets for reduced HIV incidence 
and prevalence.
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Figure 1. Total new HIV infections over the next decade, by achievement of NHAS targets
Cumulative new HIV infections at varying levels of HIV care engagement. In the base-case 
scenario, the current rates of HIV care engagement (screening, linkage, retention in care) 
persist. In the NHAS scenarios, we project improvements in care engagement (through 
increased yearly screening, improved linkage to care after diagnosis, and reduced care 
disengagement) that allows achievement of NHAS indicators 1, 4, and 5 by 2020.
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Table 1
Key model parameters
Variable Value Range for sensitivity analysis References
HIV Disease Dynamics with ART‡
Reduction in rate of transmission 93% 80-99·5% 3
Time to viral suppression on ART 6 months 2-12 months 11
Transmission Dynamics*
Annual partnerships per year 1·8 – 6·3 1·3-7·8 Calibrated*
Transmission per partnership (male to female) 2·2-3·1% 1·7-3·9% Calibrated*
Transmission per partnership (female to male) 2-2·7% 1·5-3·4% Calibrated*
Transmission per partnership (MSM) 2·9% 2·2-3·7% Calibrated*
Transmission probability per needle sharing partnership (PWID) 0·0026 0·001-0·0075 Calibrated*
Relative risk increase in transmission probability during acute HIV 12 2-24 12
Engagement in Care dynamics, base-case†
% HIV test in past 12 months 7·5-27·5% 5-35% Calibrated†
Rate of disengagement from care annually 0·175 – 0·25 0·13-0·32 13
, Calibrated†
Rate of reengagement in care annually 0·125 per year 0·09-0·16 14, 15
, Calibrated†
COSTS††
HIV test $33 $10-50 16
HIV viral load $116 $50-150 17
Outpatient Visit $129 $55-274 17
CD4 Test $49 $20-$90 17
Annual ART $32,000 $10000-$45000 18
*
Transmission in the model is a function of average partnerships per year and average probability of transmission per partnership within risk 
groups. We began with published estimates and then calibrated these parameters (Supplement for additional details and references) to fit observed 
HIV incidence and prevalence in the US and varied by gender and risk group4, 19.
†Annual HIV screening rates, percent linkage, and disengagement from care were varied by gender and risk group. To obtain parameter estimates, 
we began with published data and calibrated model to fit published estimates of HIV care engagement in the US4, 19 (Supplement for additional 
details and references). Individuals without initial linkage to care were eligible to engage in care at later times.
††We additionally included annual health care utilization costs for individuals not in care or on ART (e.g. hospitalizations, ED visits). ART 
regimen costs shown are for first line integrase inhibitor-based regimens21 ( Additional cost details and references are in Supplement).
‡All populations eligible for ART initiation regardless of CD4 count21.
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